4/11
08:06 am
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
4/11
07:36 am
mrna
Rating for MRNA
Low
Report
Rating for MRNA
4/11
07:36 am
mrna
Rating for MRNA
Low
Report
Rating for MRNA
4/9
12:09 pm
mrna
Rating for MRNA
Low
Report
Rating for MRNA
4/9
12:09 pm
mrna
Rating for MRNA
Low
Report
Rating for MRNA
4/1
05:23 pm
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "market perform" rating re-affirmed by analysts at William Blair.
Low
Report
Moderna, Inc. (NASDAQ: MRNA) had its "market perform" rating re-affirmed by analysts at William Blair.
4/1
05:23 pm
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "market perform" rating re-affirmed by analysts at William Blair.
Low
Report
Moderna, Inc. (NASDAQ: MRNA) had its "market perform" rating re-affirmed by analysts at William Blair.
3/28
11:56 am
mrna
Rating for MRNA
Report
Rating for MRNA
3/28
11:56 am
mrna
Rating for MRNA
Report
Rating for MRNA
3/28
08:07 am
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Moderna, Inc. (NASDAQ: MRNA) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
3/28
05:45 am
mrna
Rating for MRNA
Medium
Report
Rating for MRNA
3/28
05:45 am
mrna
Rating for MRNA
Medium
Report
Rating for MRNA
2/26
08:09 am
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "reduce" rating re-affirmed by analysts at HSBC Holdings plc. They now have a $86.00 price target on the stock, up previously from $75.00.
Low
Report
Moderna, Inc. (NASDAQ: MRNA) had its "reduce" rating re-affirmed by analysts at HSBC Holdings plc. They now have a $86.00 price target on the stock, up previously from $75.00.
2/26
06:45 am
mrna
Rating for MRNA
Low
Report
Rating for MRNA
2/26
06:45 am
mrna
Rating for MRNA
Low
Report
Rating for MRNA
2/23
12:15 pm
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $125.00 price target on the stock.
Low
Report
Moderna, Inc. (NASDAQ: MRNA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $125.00 price target on the stock.
2/23
12:15 pm
mrna
Moderna, Inc. (NASDAQ: MRNA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $125.00 price target on the stock.
Low
Report
Moderna, Inc. (NASDAQ: MRNA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $125.00 price target on the stock.
2/23
11:22 am
mrna
Rating for MRNA
Low
Report
Rating for MRNA
2/23
11:22 am
mrna
Rating for MRNA
Low
Report
Rating for MRNA
2/23
09:51 am
mrna
Rating for MRNA
Low
Report
Rating for MRNA